CHRONIC SPONTANEOUS URTICARIA

This study looks at the long-term safety and effectiveness of barzolvolimab in adults with chronic spontaneous urticaria (CSU), a condition causing frequent hives and itching. Participants have already completed earlier phase 3 trials. The goal is to see how well the drug control…

This study tests a new daily pill, remibrutinib, for adults with chronic spontaneous urticaria (long-term hives and itching) that antihistamines don't control well. About 470 participants will receive either remibrutinib, a placebo, or an active control (omalizumab injections) fo…

This study tests a new drug (omalizumab α) against the approved drug Xolair for people with chronic hives that don't get better with antihistamines. About 392 adults aged 15 to 75 will receive either the new drug or Xolair to see how well it reduces itching and hives over 12 week…

This study tests a new drug called barzolvolimab for people with chronic spontaneous urticaria (CSU), a condition causing long-term hives and itching that doesn't get better with standard antihistamines. About 963 adults will receive either the drug or a placebo to see if it redu…

This phase 3 study tests barzolvolimab, a new biologic drug, in 976 adults with chronic spontaneous urticaria (CSU) whose hives and itching persist despite antihistamines. Participants receive either barzolvolimab or a placebo by injection. The main goal is to see if the drug red…

This study tests the long-term safety and effectiveness of remibrutinib, a daily pill, for adults with chronic spontaneous urticaria (hives). Participants who completed earlier phase 3 trials will either continue on the drug or switch to placebo to see if symptoms return. The goa…

This study is testing the long-term safety and effectiveness of a drug called briquilimab for people with chronic hives. It includes 67 participants who have already completed a previous trial with the same drug. The goal is to see if briquilimab remains safe and helps control hi…

This trial tests a drug called briquilimab for adults with chronic spontaneous urticaria (CSU) — long-lasting hives and itching that don't get better with standard antihistamines or omalizumab. The study has three parts, with some participants getting the drug and others a placeb…

This early-stage trial tests a single dose of LP-003, a new drug for chronic spontaneous urticaria (long-lasting hives), in 12 healthy adults. The main goal is to check safety and how the body processes the drug. It is not yet tested in people with hives.

This study tests a new drug called TLL-018 in 440 adults with moderate-to-severe chronic hives (chronic spontaneous urticaria) that aren't controlled by standard antihistamines. Participants receive either TLL-018 or a placebo for 12 weeks to see if it reduces itching and hives b…

This study tested whether ritlecitinib, a drug already approved for another condition, could safely reduce hives and itching in people with chronic spontaneous urticaria (CSU). The trial planned to enroll adults aged 18–65 who have had hives for over six weeks. Participants would…

This study follows 15,000 adults and children with skin conditions like eczema, psoriasis, and vitiligo to see how well current and new treatments work in real doctor visits. It does not test a new drug but instead collects information to help doctors understand which treatments …

This study looks at how diet and oxidative stress (an imbalance of harmful molecules in the body) relate to chronic spontaneous urticaria (CSU), a condition causing itchy hives and swelling. Researchers will compare adults with active CSU to healthy volunteers, tracking their die…